One of the oldest, most prestigious medical journals, The Lancet, recently published AstraZeneca’s Phase III CASPIAN trial, of which Cancer and Hematology Centers of Western Michigan (CHCWM) was a leading site. CASPIAN showed that Imfinzi (an anti-PDL1 immunotherapy from AstraZeneca), in combination with chemotherapy, increased the survival of patients with extensive-stage small cell lung cancer.
CHCWM was a leading site for the CASPIAN trial among 209 centers across 22 countries. Primary CHCWM employees involved in the study included principal investigator Dr. Yuanbin Chen, M.D., Ph.D.; primary study coordinator Penny Berger and data manager Karen Kuiper. The trial was also presented at the International Association for the Study of Lung Cancer’s 2019 World Conference on Lung Cancer in Barcelona, Spain last month. To read more about this trial, visit The Lancet at https://bit.ly/2VkOEJ5.
Founded in 1979, CHCWM has grown to become the largest physician-owned oncology and hematology practice in Michigan. We deliver advanced care in a personal way, and our expertise and caring approach make us dedicated to the help, healing and hope for cancer patients and their families. Thanks to the hard work of our growing staff, CHCWM has been named one of the Nation’s Best and Brightest Companies to Work For®. To learn more about CHCWM, visit chcwm.com.
Becky Downing, Social Media & Marketing Specialist